- Entity formation
- Entity management
- M&A transaction support
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Structures implementation and management
- Private client services
- Reporting services
Explore content
Show all >Featured articles and media

Insights | Corporate Client Services
Voluntary carbon credits bolster green bonds
25 May 2023
Read >
Featured articles and media
Show all media for Private Capital & Hedge Fund Services >Featured articles and media
Show all media for Capital Markets >Featured articles and media
Show all media for Private Clients >Featured events

Events | Virtual
Private Funds Industry Live, Expanding Private Funds in Global Markets
10 Jan 2023
Watch the recording >
Events | Virtual
Private Funds Industry Live, Demystifying Private Capital Funds
6 Dec 2022
Watch the recording >
Events | Virtual
State of the Market and Growing your Business – Setting up and Maintaining WFOEs in China
15 Nov 2022
Watch the recording >- Home
- Our services
- Corporate Client Services
- Entity formation
- Entity management
- M&A transaction support
- Private Capital & Hedge Fund Services
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- Capital Markets
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Private Clients
- Structures implementation and management
- Private client services
- Reporting services
- Corporate Client Services
- Our locations
- About us
- News & Insights
- Login
Case study
Supporting Portola Pharmaceuticals Inc.
11 November 2020

Portola Pharmaceuticals Inc. (“Portola”) is a San Francisco based biopharmaceutical company founded in 2003 with the mission to advance patient care in thrombosis and other hematologic disorders.
Portola elected to set up its trading company in the Netherlands due to its proximity to the European Medicines Agency (EMA) and the port of Rotterdam. In the Netherlands Portola will use a third party logistics (3PL) service provider to distribute products to wholesalers and local hospitals in various countries in Europe.
The solution
In order to trade it’s Its product Ondexxya – an antidote for medications Rivaroxaban and Apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding – it needed to set up a Dutch limited liability company (Besloten Vennootschap) in 2018 to function as the trading entity in Europe for Portola.
Our advantages
We supported Portola during the set up phase in Europe and will continued to do so when it became operational. As part of this Intertrust Group helped with the incorporation of the Dutch trading company, management services, recruitment services, product registration in the EU, payment services and legal assistance for the contracts to be concluded by the Dutch trading company. In addition, Intertrust Group and Portola have, in conjunction with Portola’s advisers, set up and implemented a governance model suitable for Portola’s European business.